A diagnostic test that is assigned to accompany a personalised drug therapy is called a Companion Diagnostics (CDx). There are many advantages of therapy-accompanying diagnostics. By means of an individual risk assessment, the side effects in treated patients are reduced. In addition, the existing status quo in the patient can be detected at an early stage of a disease, which enables earlier intervention and improves the chance of complete remission. Diagnoses can be made more accurately, as the same symptoms can be attributed to different causes. This enables specific, direct and effective therapy.

We are currently conducting studies for various manufacturers of osteoporosis drugs and for different groups of active substances, which can, among other things, test the effectiveness, possible dosages and the duration of the possible therapy.

For example, studies are currently underway in Kiel with the monoclonal antibody denosumab and in Leuven (Belgium) with androgen hormone inhibitors. Both studies are to be published in scientific journals in 2021. Do you also have a potential Companion Diagnostic project? Then contact our managing director Dr. Stefan Kloth.